1177.HK Sino Biopharmaceutical Limited Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
03:36
Jan 23
Jan 23
Sino Bio pipeline and licensing offer growth
Sino Biopharmaceuticals will stay focused on oncology, hepatitis, surgery, and respiratory areas while exploring cardiovascular and metabolism. It has good molecules attracting big pharma interest and expects M&A, licensing, and partnership opportunities to drive growth.
MED
04:48
Jan 14
Jan 14
Sino BioPharma innovation pipeline strengthens
Sino Biopharma has transformed from generics to one of China’s leading innovative pharma companies with strong oncology and chronic disease positions; recent acquisitions of Inova and Hai Jia add 20+ innovative programs in cardiovascular and weight loss, and abundant cash supports continued M&A and R&D.
HIGH
About 1177.HK Investor Commentary
Across the available history and selected sources, Buzzberg tracks 1177.HK (Sino Biopharmaceutical Limited) across 1 sources: 2 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: Eric Tse, Theresa Tse.